Literature DB >> 19130899

Subjective perception of cognition is related to mood and not performance.

S E Marino1, K J Meador, D W Loring, M S Okun, H H Fernandez, A J Fessler, R P Kustra, J M Miller, P G Ray, A Roy, M R Schoenberg, V J Vahle, M A Werz.   

Abstract

OBJECTIVE: Clinicians monitor cognitive effects of drugs primarily by asking patients to describe their side effects. We examined the relationship of subjective perception of cognition to mood and objective cognitive performance in healthy volunteers and neurological patients.
METHODS: Three separate experiments used healthy adults treated with lamotrigine (LTG) and topiramate (TPM), adults with epilepsy on LTG or TPM, and patients with idiopathic Parkinson's disease. Correlations were calculated for change scores on and off drugs in the first two experiments and for the single assessment in Experiment 3.
RESULTS: Across all three experiments, significant correlations were more frequent (chi(2)=259, P < or = 0.000) for mood versus subjective cognitive perception (59%) compared with subjective versus objective cognition (2%) and mood versus objective cognitive performance (2%).
CONCLUSIONS: Subjective perception of cognitive effects is related more to mood than objective performance. Clinicians should be aware of this relationship when assessing patients' cognitive complaints.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19130899      PMCID: PMC2688662          DOI: 10.1016/j.yebeh.2008.12.007

Source DB:  PubMed          Journal:  Epilepsy Behav        ISSN: 1525-5050            Impact factor:   2.937


  39 in total

Review 1.  Memory and epilepsy: current perspectives.

Authors:  B P Hermann; M Seidenberg; A R Woodard
Journal:  Clin Nurs Pract Epilepsy       Date:  1996-12

2.  The Mattis Dementia Rating Scale: normative data from 1,001 healthy volunteers.

Authors:  R Schmidt; W Freidl; F Fazekas; B Reinhart; P Grieshofer; M Koch; B Eber; M Schumacher; K Polmin; H Lechner
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

3.  A one-year open-label trial of risperidone augmentation in lithium nonresponder youth with preschool-onset bipolar disorder.

Authors:  Mani N Pavuluri; David B Henry; Julie A Carbray; Gwen A Sampson; Michael W Naylor; Philip G Janicak
Journal:  J Child Adolesc Psychopharmacol       Date:  2006-06       Impact factor: 2.576

4.  The short form of the Geriatric Depression Scale: a comparison with the 30-item form.

Authors:  W J Burke; W H Roccaforte; S P Wengel
Journal:  J Geriatr Psychiatry Neurol       Date:  1991 Jul-Sep       Impact factor: 2.680

5.  The relationship of neuropsychological functioning to quality of life in epilepsy.

Authors:  K Perrine; B P Hermann; K J Meador; B G Vickrey; J A Cramer; R D Hays; O Devinsky
Journal:  Arch Neurol       Date:  1995-10

6.  Epilepsy and poor memory: who complains and what do they mean?

Authors:  R Corcoran; P Thompson
Journal:  Br J Clin Psychol       Date:  1993-05

7.  Subjective perception of cognitive deficit in psychotic patients.

Authors:  Julio Sanjuán; Eduardo-Jesus Aguilar; Jose Manuel Olivares; Salvador Ros; Angel Luis Montejo; Fermin Mayoral; Miguel Angel Gonzalez-Torres; Manuel Bousoño
Journal:  J Nerv Ment Dis       Date:  2006-01       Impact factor: 2.254

8.  Memory complaints in epilepsy: correlations with cognitive performance and neuroticism.

Authors:  J Vermeulen; A P Aldenkamp; W C Alpherts
Journal:  Epilepsy Res       Date:  1993-06       Impact factor: 3.045

9.  A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs.

Authors:  S G Uijl; C S M P Uiterwaal; A P Aldenkamp; J A Carpay; J C Doelman; K Keizer; C J Vecht; M C de Krom; C A van Donselaar
Journal:  Seizure       Date:  2006-03-23       Impact factor: 3.184

10.  Neuropsychological and neurophysiologic effects of carbamazepine and levetiracetam.

Authors:  K J Meador; A Gevins; D W Loring; L K McEvoy; P G Ray; M E Smith; G K Motamedi; B M Evans; C Baum
Journal:  Neurology       Date:  2007-11-27       Impact factor: 9.910

View more
  18 in total

1.  Epilepsy: maximizing cognitive outcomes in epilepsy.

Authors:  David W Loring; Kimford J Meador
Journal:  Nat Rev Neurol       Date:  2012-07-10       Impact factor: 42.937

2.  The cognition and emotional well-being indices of the Parkinson's disease questionnaire-39: what do they really measure?

Authors:  Jacob D Jones; Chris Hass; Paul Mangal; Jacob Lafo; Michael S Okun; Dawn Bowers
Journal:  Parkinsonism Relat Disord       Date:  2014-09-18       Impact factor: 4.891

3.  Personality determinants of subjective executive function in older adults.

Authors:  Tyler Bell; Nikki Hill; Despina Stavrinos
Journal:  Aging Ment Health       Date:  2019-09-27       Impact factor: 3.658

4.  Antiepileptic drug effects on subjective and objective cognition.

Authors:  Robert J Quon; Morgan T Mazanec; Samantha S Schmidt; Angeline S Andrew; Robert M Roth; Todd A MacKenzie; Martha Sajatovic; Tanya Spruill; Barbara C Jobst
Journal:  Epilepsy Behav       Date:  2020-01-29       Impact factor: 2.937

Review 5.  Opioid modulation of cognitive impairment in depression.

Authors:  Moriah L Jacobson; Hildegard A Wulf; Caroline A Browne; Irwin Lucki
Journal:  Prog Brain Res       Date:  2018-09-18       Impact factor: 2.453

Review 6.  Cognitive and neurodevelopmental effects of antiepileptic drugs.

Authors:  Rebecca L Bromley; Beth A Leeman; Gus A Baker; Kimford J Meador
Journal:  Epilepsy Behav       Date:  2011-06-17       Impact factor: 2.937

7.  Prospective memory deficits are associated with poorer everyday functioning in Parkinson's disease.

Authors:  Eva Pirogovsky; Steven Paul Woods; J Vincent Filoteo; Paul E Gilbert
Journal:  J Int Neuropsychol Soc       Date:  2012-07-30       Impact factor: 2.892

Review 8.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

9.  Cognitive effects of donepezil therapy in patients with brain tumors: a pilot study.

Authors:  Denise D Correa; Maria Kryza-Lacombe; Raymond E Baser; Kathryn Beal; Lisa M DeAngelis
Journal:  J Neurooncol       Date:  2016-01-06       Impact factor: 4.130

Review 10.  Topiramate and cognitive impairment: evidence and clinical implications.

Authors:  Marco Mula
Journal:  Ther Adv Drug Saf       Date:  2012-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.